GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi India Ltd (NSE:SANOFI) » Definitions » Construction In Progress

Sanofi India (NSE:SANOFI) Construction In Progress : ₹0 Mil (As of Mar. 2025)


View and export this data going back to 2003. Start your Free Trial

What is Sanofi India Construction In Progress?

Sanofi India's quarterly construction in progress increased from Sep. 2024 (₹0 Mil) to Dec. 2024 (₹187 Mil) but then declined from Dec. 2024 (₹187 Mil) to Mar. 2025 (₹0 Mil).

Sanofi India's annual construction in progress declined from Dec. 2022 (₹229 Mil) to Dec. 2023 (₹153 Mil) but then increased from Dec. 2023 (₹153 Mil) to Dec. 2024 (₹187 Mil).


Sanofi India Construction In Progress Historical Data

The historical data trend for Sanofi India's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi India Construction In Progress Chart

Sanofi India Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.00 98.00 229.00 153.00 187.00

Sanofi India Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 294.00 - 187.00 -

Sanofi India Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Sanofi India Business Description

Traded in Other Exchanges
Address
Saki Vihar Road, Sanofi House, CTS Number 117-B, L&T Business Park, Powai, Mumbai, MH, IND, 400072
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and other export markets.

Sanofi India Headlines

No Headlines